Drug information of Menotropins
Menotropins are a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH and LH are important in the development of follicles (eggs) that are produced by the ovaries in women. Menotropins are used to help your body produce multiple eggs during ovulation, in preparation for in-vitro fertilization.
Mechanism of effect
Stimulates ovarian follicular growth in women who do not have primary ovarian failure
Used to treat female infertility, Menotropins stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle.
Menopur Mean follicle-stimulating hormone (FSH) C max is 8.5 milliunit/mL (subcutaneous) and 7.8 milliunit/mL (IM); mean FSH AUC is 762 milliunit•h/mL (subcutaneous) and 656.1 milliunit•h/mL (IM); median T max is 17.9 h (subcutaneous) and 27.5 h (IM). Mean FSH t ½ is 11 to 13 h.
Drug indicationsFollicle Stimulation
Ovulation induction: Initial dose: 150 international units SC or IM daily for the first 5 days of treatment. Maximum dose: 450 international units daily Duration of therapy: 7 to 12 days
Drug contraindicationsPregnancy , hypersensitivity to drug or its components. , primary ovarian failure , adrenal dysfunction , abnormal uterine bleeding of undetermined origin , ovarian enlargement
Side effectsMigraine , nausea , Headache , constipation , Tachycardia , abdominal pain , dizziness , vomiting , rash , flushing , Diarrhea , Flu-like symptoms , Injection-site reaction , malaise , Cardiovascular disorder , hemorrhage , Hypersensitivity , Multiple pregnancies , mild to moderate ovarian enlargement
1-Before treatment, a thorough gynecologic and endocrinologic evaluation must be performed. Evaluate estradiol levels and ultrasonography results for monitoring growth and development of follicles, timing of hCG administration, and minimizing risk of OHSS and multiple gestation. 2-Monitor patient for signs of excessive ovarian stimulation (eg, abdominal pain or distension, diarrhea, dyspnea, nausea, oliguria, rapid weight gain, severe pelvic pain, vomiting). 3-Monitor patient for signs and symptoms of thromboembolic events (eg, arterial occlusion, pulmonary embolism, pulmonary infarction, stroke, venous thrombophlebitis). 4-Multiple pregnancies have occurred
Points of recommendation
1-To minimize bleeding, do not rub site after injection. 2-OHSS May occur. Warning signs include abdominal distention, nausea, oliguria, pelvic pain, vomiting, weight gain. May progress within 24 h to several days to become a serious medical reaction. 3--If inadequate follicle development or ovulation without subsequent pregnancy, treatment may be repeated.